# Jeil Pharmaceutical Co., Ltd. clinical trials: 38 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 38 trials with Jeil Pharmaceutical Co., Ltd. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Jeil Pharmaceutical Co., Ltd.: 38 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/jeil-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 38
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 38, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07937059 | Observational Study With Erosive Gastroesophageal Reflux Disease With JAQBO® ODT | Jeil Pharmaceutical Co., Ltd. | Observational | Completed | Erosive Gastroesophageal Reflux Disease | 5,183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937059) |
| October 26, 2026 | NCT07894939 | Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Zastaprazan Citrate | Jeil Pharmaceutical Co., Ltd. | Observational | Recruiting | Erosive Gastroesophageal Reflux Disease | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894939) |
| August 11, 2025 | NCT07115706 | JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD | Jeil Pharmaceutical Co., Ltd. | Observational | Not yet recruiting | Erosive Gastroesophageal Reflux Disease | 7,150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115706) |
| May 1, 2025 | NCT06952855 | Observationa Study is a Prospective and Multi-institutional Observational Study. | Jeil Pharmaceutical Co., Ltd. | Observational | Completed | Erosive Reflux Disease, Heartburn, Acid Regurgitation | 5,536 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06952855) |
| May 28, 2024 | NCT06431399 | To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004 | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Unknown | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06431399) |
| December 15, 2023 | NCT06171880 | To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901 | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Adult | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06171880) |
| December 13, 2023 | NCT06169059 | To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004 | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Adult | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06169059) |
| December 12, 2023 | NCT06165965 | To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008 | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Adult | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06165965) |
| November 22, 2023 | NCT06144788 | Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients | Jeil Pharmaceutical Co., Ltd. | Phase 2 | Completed | Type 2 Diabetes Mellitus | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06144788) |
| March 25, 2022 | NCT05296044 | To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and... | Jeil Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Type 2 Diabetes Mellitus | 245 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05296044) |
| December 29, 2021 | NCT05172622 | Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 in Healthy Subjects | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Unknown | Diabetes Mellitus | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05172622) |
| November 1, 2021 | NCT05101135 | To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and... | Jeil Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Type 2 Diabetes Mellitus | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05101135) |
| June 8, 2021 | NCT04917315 | To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder | Jeil Pharmaceutical Co., Ltd. | Phase 3 | Completed | Overactive Bladder | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04917315) |
| June 4, 2021 | NCT04914221 | The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Completed | Overactive Bladder(OAB) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04914221) |
| April 27, 2021 | NCT04861233 | A Study of Lubiprostone to Treat Constipation | Jeil Pharmaceutical Co., Ltd. | Observational | Unknown | Constipation | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04861233) |
| October 16, 2018 | NCT03707899 | The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers... | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Completed | Hypertension With Dyslipidemia | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03707899) |
| October 1, 2018 | NCT03690778 | The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers. | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Completed | Diabetes, Hyperlipidemias | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03690778) |
| June 20, 2018 | NCT03564405 | Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma | Jeil Pharmaceutical Co., Ltd. | Not applicable | Completed | Hepatocellular Carcinoma Non-resectable | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03564405) |
| May 23, 2018 | NCT03533920 | Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma | Jeil Pharmaceutical Co., Ltd. | Not applicable | Completed | Hepatocellular Carcinoma Non-resectable | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03533920) |
| March 9, 2018 | NCT03461081 | Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Completed | Hypertension With Hyperlipidemia | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03461081) |
| December 26, 2017 | NCT03383042 | Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy... | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Completed | Anti-Ulcer Agents | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03383042) |
| December 5, 2017 | NCT03362008 | Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix and Champix in Healthy Adult Male Subjects. | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Completed | Smoking, Cigarette | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03362008) |
| August 11, 2017 | NCT03247140 | The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers... | Jeil Pharmaceutical Co., Ltd. | Phase 1 | Completed | Hypertension With Dyslipidemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03247140) |
| March 23, 2017 | NCT03088254 | Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin | Jeil Pharmaceutical Co., Ltd. | Phase 3 | Completed | Dyslipidemia With Hypertension | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03088254) |
| February 23, 2017 | NCT03062397 | Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke | Jeil Pharmaceutical Co., Ltd. | Phase 2 | Unknown | Acute Ischemic Stroke | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03062397) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 21 |
| Phase 2 | 3 |
| Phase 3 | 6 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 30 |
| Unknown | 6 |
| Recruiting | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Urinary Bladder, Overactive | 5 |
| Diabetes Mellitus | 5 |
| Hyperlipidemias | 5 |
| Prostatic Hyperplasia | 4 |
| Diabetes Mellitus, Type 2 | 4 |
| Lower Urinary Tract Symptoms | 2 |
| Stroke | 2 |
| Ischemic Stroke | 1 |
| Essential Hypertension | 1 |
| Coronary Aneurysm | 1 |
| Dyslipidemias | 1 |
| Heartburn | 1 |
| Gastroesophageal Reflux | 1 |
| Constipation | 1 |
| Cigarette Smoking | 1 |
| Hypertension | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [B2B scientific equipment companies in the United States](https://specstream.ai/data/businesses/b2b-scientific-equipment-companies/united-states)
- [Printing companies in the United States](https://specstream.ai/data/businesses/printing-companies/united-states)
- [Fingerprinting services in the United States](https://specstream.ai/data/businesses/fingerprinting-services/united-states)
- [Aircraft service companies in the United States](https://specstream.ai/data/businesses/aircraft-service-companies/united-states)
- [Orthopedic surgery practices in the United States](https://specstream.ai/data/businesses/orthopedic-surgery-practices/united-states)
